{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:47:50Z","timestamp":1782409670335,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10147-026-03053-8","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:24:11Z","timestamp":1779211451000},"page":"1370-1380","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of prior primary tumor resection on long-term prognosis in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab: a multicenter analysis"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7402-6164","authenticated-orcid":false,"given":"Shimpei","family":"Yamashita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzo","family":"Hamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Tomida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makito","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriya","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Kohjimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"issue":"14","key":"3053_CR1","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Ar\u00e9n Frontera O, Melichar B, Choueiri TK, Plimack ER, Barth\u00e9l\u00e9my P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378(14):1277\u20131290. https:\/\/doi.org\/10.1056\/NEJMoa1712126","journal-title":"N Engl J Med"},{"issue":"12","key":"3053_CR2","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Souli\u00e8res D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1116\u20131127. https:\/\/doi.org\/10.1056\/NEJMoa1816714","journal-title":"N Engl J Med"},{"issue":"12","key":"3053_CR3","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH Jr., Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK (2019) Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1103\u20131115. https:\/\/doi.org\/10.1056\/NEJMoa1816047","journal-title":"N Engl J Med"},{"issue":"10189","key":"3053_CR4","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/s0140-6736(19)30723-8","volume":"393","author":"BI Rini","year":"2019","unstructured":"Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, Choueiri TK, Parnis F, Khaznadar T, Thobhani A, Li S, Piault-Louis E, Frantz G, Huseni M, Schiff C, Green MC, Motzer RJ (2019) Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 393(10189):2404\u20132415. https:\/\/doi.org\/10.1016\/s0140-6736(19)30723-8","journal-title":"Lancet"},{"issue":"9","key":"3053_CR5","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Ju\u00e1rez VM, Hsieh JJ, Basso U, Shah AY, Su\u00e1rez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, \u017bo\u0142nierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ (2021) Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 384(9):829\u2013841. https:\/\/doi.org\/10.1056\/NEJMoa2026982","journal-title":"N Engl J Med"},{"issue":"14","key":"3053_CR6","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Gr\u00fcnwald V, Hutson TE, Kopyltsov E, M\u00e9ndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK (2021) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 384(14):1289\u20131300. https:\/\/doi.org\/10.1056\/NEJMoa2035716","journal-title":"N Engl J Med"},{"issue":"11","key":"3053_CR7","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","volume":"35","author":"NM Tannir","year":"2024","unstructured":"Tannir NM, Albig\u00e8s L, McDermott DF, Burotto M, Choueiri TK, Hammers HJ, Barth\u00e9l\u00e9my P, Plimack ER, Porta C, George S, Donskov F, Atkins MB, Gurney H, Kollmannsberger CK, Grimm MO, Barrios C, Tomita Y, Castellano D, Gr\u00fcnwald V, Rini BI, Jiang R, Desilva H, Fedorov V, Lee CW, Motzer RJ (2024) Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. Ann Oncol 35(11):1026\u20131038. https:\/\/doi.org\/10.1016\/j.annonc.2024.07.727","journal-title":"Ann Oncol"},{"issue":"3","key":"3053_CR8","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.eururo.2021.10.001","volume":"81","author":"L Albiges","year":"2022","unstructured":"Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barth\u00e9l\u00e9my P, Porta C, Powles T, Donskov F, George S, Kollmannsberger CK, Gurney H, Grimm MO, Tomita Y, Castellano D, Rini BI, Choueiri TK, Leung D, Saggi SS, Lee CW, McHenry MB, Motzer RJ (2022) First-line nivolumab plus ipilimumab versus sunitinib in patients without nephrectomy and with an evaluable primary renal tumor in the CheckMate 214 Trial. Eur Urol 81(3):266\u2013271. https:\/\/doi.org\/10.1016\/j.eururo.2021.10.001","journal-title":"Eur Urol"},{"issue":"10","key":"3053_CR9","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1007\/s10147-022-02215-8","volume":"27","author":"T Kato","year":"2022","unstructured":"Kato T, Fujita K, Minami T, Nagahara A, Hyashi Y, Nakata W, Matsuzaki K, Nakano K, Hatano K, Kawashima A, Imamura R, Takada S, Nishimura K, Tsujihata M, Takao T, Nakai Y, Nakayama M, Nishimura K, Uemura M, Uemura H, Nonomura N (2022) Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective study. Int J Clin Oncol 27(10):1596\u20131604. https:\/\/doi.org\/10.1007\/s10147-022-02215-8","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"3053_CR10","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/jjco\/hyae046","volume":"54","author":"K Ohba","year":"2024","unstructured":"Ohba K, Nakanishi H, Kawada K, Nakamura Y, Mitsunari K, Matsuo T, Mochizuki Y, Imamura R (2024) Predictive factors of nivolumab plus ipilimumab treatment efficacy in metastatic renal cell carcinoma patients. Jpn J Clin Oncol 54(7):827\u2013832. https:\/\/doi.org\/10.1093\/jjco\/hyae046","journal-title":"Jpn J Clin Oncol"},{"issue":"9","key":"3053_CR11","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/iju.15193","volume":"30","author":"T Hara","year":"2023","unstructured":"Hara T, Furukawa J, Shiraishi Y, Okamura Y, Bando Y, Terakawa T, Harada K, Nakano Y, Fujisawa M (2023) Impact of cytoreductive nephrectomy prior to combination therapy of ipilimumab plus nivolumab in metastatic renal cell carcinoma. Int J Urol 30(9):746\u2013752. https:\/\/doi.org\/10.1111\/iju.15193","journal-title":"Int J Urol"},{"issue":"1","key":"3053_CR12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","volume":"70","author":"H Moch","year":"2016","unstructured":"Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol 70(1):93\u2013105. https:\/\/doi.org\/10.1016\/j.eururo.2016.02.029","journal-title":"Eur Urol"},{"issue":"34","key":"3053_CR13","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1200\/jco.2008.21.4809","volume":"27","author":"DY Heng","year":"2009","unstructured":"Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27(34):5794\u20135799. https:\/\/doi.org\/10.1200\/jco.2008.21.4809","journal-title":"J Clin Oncol"},{"issue":"2","key":"3053_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"issue":"1","key":"3053_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed) 112(1):90\u201392. https:\/\/doi.org\/10.1016\/j.ad.2019.05.009","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"5","key":"3053_CR16","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.euo.2021.03.001","volume":"4","author":"F Quhal","year":"2021","unstructured":"Quhal F, Mori K, Bruchbacher A, Resch I, Mostafaei H, Pradere B, Schuettfort VM, Laukhtina E, Egawa S, Fajkovic H, Remzi M, Shariat SF, Schmidinger M (2021) First-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol Oncol 4(5):755\u2013765. https:\/\/doi.org\/10.1016\/j.euo.2021.03.001","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"3053_CR17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.clgc.2023.09.009","volume":"22","author":"E Esterberg","year":"2024","unstructured":"Esterberg E, Iyer S, Nagar SP, Davis KL, Tannir NM (2024) Real-world treatment patterns and clinical outcomes among patients with advanced renal cell carcinoma. Clin Genitourin Cancer 22(2):115\u2013125e113. https:\/\/doi.org\/10.1016\/j.clgc.2023.09.009","journal-title":"Clin Genitourin Cancer"},{"issue":"11","key":"3053_CR18","doi-asserted-by":"publisher","first-page":"e7196","DOI":"10.1002\/cam4.7196","volume":"13","author":"G Kimura","year":"2024","unstructured":"Kimura G, Fujii Y, Osawa T, Uchitomi Y, Honda K, Kondo M, Otani A, Wako T, Kawai D, Mitsuda Y, Sakashita N, Shinohara N (2024) Cross-sectional study of therapy-related expectations\/concerns of patients with metastatic renal cell carcinoma and physicians in Japan. Cancer Med 13(11):e7196. https:\/\/doi.org\/10.1002\/cam4.7196","journal-title":"Cancer Med"},{"issue":"25","key":"3053_CR19","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1200\/jco.21.02938","volume":"40","author":"MB Atkins","year":"2022","unstructured":"Atkins MB, Jegede OA, Haas NB, McDermott DF, Bilen MA, Stein M, Sosman JA, Alter R, Plimack ER, Ornstein M, Hurwitz M, Peace DJ, Signoretti S, Denize T, Cimadamore A, Wu CJ, Braun D, Einstein D, Catalano PJ, Hammers H (2022) Phase II study of nivolumab and salvage nivolumab\/ipilimumab in treatment-naive patients with advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A). J Clin Oncol 40(25):2913\u20132923. https:\/\/doi.org\/10.1200\/jco.21.02938","journal-title":"J Clin Oncol"},{"issue":"10","key":"3053_CR20","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1007\/s10147-024-02593-1","volume":"29","author":"T Nakayama","year":"2024","unstructured":"Nakayama T, Takeshita H, Kagawa M, Washino S, Shirotake S, Miura Y, Hyodo Y, Izumi K, Inoue M, Matsuoka Y, Miyagawa T, Oyama M, Saito K, Kawakami S (2024) Prognostic significance of inflammatory markers in patients with advanced renal cell carcinoma receiving nivolumab plus ipilimumab. Int J Clin Oncol 29(10):1528\u20131537. https:\/\/doi.org\/10.1007\/s10147-024-02593-1","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"3053_CR21","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/ijc.33560","volume":"149","author":"O Alhalabi","year":"2021","unstructured":"Alhalabi O, Hasanov E, Wilson NR, Araujo J, Wang J, Campbell MT, Goswami S, Shah AY, Gao J, Msaouel P, Tannir NM (2021) Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: the MD Anderson Cancer Center experience. Int J Cancer 149(2):387\u2013393. https:\/\/doi.org\/10.1002\/ijc.33560","journal-title":"Int J Cancer"},{"key":"3053_CR22","doi-asserted-by":"publisher","unstructured":"Motzer RJ, Choueiri TK, McDermott DF, Powles T, Vano YA, Gupta S, Yao J, Han C, Ammar R, Papillon-Cavanagh S, Saggi SS, McHenry MB, Ross-Macdonald P, Wind-Rotolo M (2022) Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. J Immunother Cancer 10(3). https:\/\/doi.org\/10.1136\/jitc-2021-004316","DOI":"10.1136\/jitc-2021-004316"},{"issue":"6","key":"3053_CR23","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/jjco\/hyae031","volume":"54","author":"S Yamashita","year":"2024","unstructured":"Yamashita S, Hamamoto S, Furukawa J, Fujita K, Takahashi M, Miyake M, Ito N, Iwamoto H, Kohjimoto Y, Hara I (2024) Association of lung immune prognostic index with survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. Jpn J Clin Oncol 54(6):722\u2013729. https:\/\/doi.org\/10.1093\/jjco\/hyae031","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"3053_CR24","doi-asserted-by":"publisher","first-page":"12398","DOI":"10.1038\/s41598-024-63403-2","volume":"14","author":"S Yamashita","year":"2024","unstructured":"Yamashita S, Hamamoto S, Furukawa J, Fujita K, Takahashi M, Miyake M, Ito N, Iwamoto H, Kohjimoto Y, Hara I (2024) Prognostic impact of FAN score in patients receiving nivolumab plus ipilimumab for metastatic renal cell carcinoma. Sci Rep 14(1):12398. https:\/\/doi.org\/10.1038\/s41598-024-63403-2","journal-title":"Sci Rep"},{"issue":"1","key":"3053_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3233\/kca-210010","volume":"6","author":"H Bell","year":"2022","unstructured":"Bell H, Cotta BH, Salami SS, Kim H, Vaishampayan U (2022) PROBEing the role of cytoreductive nephrectomy in advanced renal cancer. Kidney Cancer 6(1):3\u20139. https:\/\/doi.org\/10.3233\/kca-210010","journal-title":"Kidney Cancer"},{"issue":"1","key":"3053_CR26","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s12885-024-11987-3","volume":"24","author":"L Iisager","year":"2024","unstructured":"Iisager L, Ahrenfeldt J, Donskov F, Ljungberg B, Bex A, Lund L, Lyskj\u00e6r I, Fristrup N (2024) Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial. BMC Cancer 24(1):260. https:\/\/doi.org\/10.1186\/s12885-024-11987-3","journal-title":"BMC Cancer"},{"issue":"9","key":"3053_CR27","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1158\/1078-0432.ccr-15-1823","volume":"23","author":"YG Najjar","year":"2017","unstructured":"Najjar YG, Rayman P, Jia X, Pavicic PG Jr., Rini BI, Tannenbaum C, Ko J, Haywood S, Cohen P, Hamilton T, Diaz-Montero CM, Finke J (2017) Myeloid-derived suppressor cell subset accumulation in renal cell carcinoma parenchyma is associated with intratumoral expression of IL1\u03b2, IL8, CXCL5, and Mip-1\u03b1. Clin Cancer Res 23(9):2346\u20132355. https:\/\/doi.org\/10.1158\/1078-0432.ccr-15-1823","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3053_CR28","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.imlet.2015.10.001","volume":"168","author":"A Fl\u00f6rcken","year":"2015","unstructured":"Fl\u00f6rcken A, Takvorian A, Singh A, Gerhardt A, Ostendorf BN, D\u00f6rken B, Pezzutto A, Westermann J (2015) Myeloid-derived suppressor cells in human peripheral blood: optimized quantification in healthy donors and patients with metastatic renal cell carcinoma. Immunol Lett 168(2):260\u2013267. https:\/\/doi.org\/10.1016\/j.imlet.2015.10.001","journal-title":"Immunol Lett"},{"issue":"1","key":"3053_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13058-019-1189-x","volume":"21","author":"M Bosiljcic","year":"2019","unstructured":"Bosiljcic M, Cederberg RA, Hamilton MJ, LePard NE, Harbourne BT, Collier JL, Halvorsen EC, Shi R, Franks SE, Kim AY, Ban\u00e1th JP, Hamer M, Rossi FM, Bennewith KL (2019) Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs. Breast Cancer Res 21(1):103. https:\/\/doi.org\/10.1186\/s13058-019-1189-x","journal-title":"Breast Cancer Res"},{"issue":"2","key":"3053_CR30","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/mou.0000000000001077","volume":"33","author":"DE Magee","year":"2023","unstructured":"Magee DE, Helstrom E, Kutikov A (2023) The role of cytoreductive nephrectomy in the immuno-oncological therapy era. Curr Opin Urol 33(2):136\u2013141. https:\/\/doi.org\/10.1097\/mou.0000000000001077","journal-title":"Curr Opin Urol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03053-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03053-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03053-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:19:10Z","timestamp":1782407950000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03053-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3053"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03053-8","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"28 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shimpei Yamashita reports honoraria\/fees from Eisai. Shuzo Hamamoto reports honoraria\/fees from Eisai, Ono Pharmaceutical, MSD and Bayer, and research funding from Daiwa Securities Foundation and Toyoaki Scholarship Foundation. Makito Miyake reports honoraria\/fees from Ono Pharmaceutical. Junya Furukawa reports honoraria\/fees from Ono Pharmaceutical and Bristol Myers Squibb. Kazutoshi Fujita reports honoraria\/fees from Ono Pharmaceutical, Bristol Myers Squibb, Astellas, Takeda, Eisai, Pfizer, Janssen, AstraZeneca, Merck Biopharma, MSD and Ferring. Isao Hara reports honoraria\/fees from Janssen, Astellas, Takeda and Bayer. Yasuo Kohjimoto reports honoraria\/fees from Ono Pharmaceutical. Yukari Bando, Shingo Toyoda, Ryotaro Tomida, Noriyuki Ito and Noriya Yamaguchi declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the Wakayama Medical University Institutional Review Board (approval number 3470) and the ethics committees of all participating institutions. Patient consent for participation was obtained using the opt-out method.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}